Sökning: "antiplatelet drug"

Visar resultat 6 - 10 av 10 avhandlingar innehållade orden antiplatelet drug.

1. 6. Kinetic Models in Life Science — Contributions to Methods and Applications

   Författare :Joachim Almquist; Stiftelsen Fraunhofer-Chalmers Centrum för Industrimatematik (FCC); []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NLME modeling; kinetic models; FOCE; Mig1; cell-to-cell variability; pharmacokinetics; parameter estimation; ticagrelor; atrial fibrillation; Kv1.5;

   Sammanfattning : Kinetic models in life science combine mathematics and biology to answer questions from areas such as cell biology, physiology, biotechnology, and drug development. The idea of kinetic models is to represent a biological system by a number of biochemical reactions together with mathematical expressions for the reaction kinetics, i.e. LÄS MER

3. 7. Outcome of Stroke Prevention : Analyses Based on Data from Riks-Stroke and Other Swedish National Registers

   Författare :Signild Åsberg; Andreas Terént; Hélène Pessah; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Stroke; Epidemiology; Age groups; Risk factors; Atrial fibrillation; Secondary prevention; Anticoagulants; Antiplatelets; Hemorrhage; Mortality.; Medicinsk vetenskap; Medical Science;

   Sammanfattning : The aim of this thesis was to explore variations in stroke prevention and the effect of prevention on outcome. The studies were based on patients registered in the Swedish Stroke Register between 2001 and 2009 and although used to different extents in each paper, additional information was retrieved through linkage to The National Patient Register, the Cause of Death Register, the Prescribed Drug Register and the Total Population Register. LÄS MER

4. 8. Platelet Inhibition and Bleeding in Coronary Artery Bypass Surgery

   Författare :Ulrica Alström; Elisabeth Ståhle; Ulf Schött; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; bleeding; cardiac surgery; platelet inhibition; re-exploration; cost analysis; Anaesthetics and intensive care; Anestesiologi och intensivvård; Thoraxkirurgi; Thorax Surgery; Anaesthesiology and Intensive Care; Anestesiologi och intensivvård;

   Sammanfattning : A substantial number of patients undergoing cardiac surgery are on dual anti-platelet treatment with clopidogrel and aspirin. A disadvantage with this treatment is increased risk of bleeding. Bleeding is a complication of major concern associated with adverse outcome for the patient and increased hospital resource utilization. LÄS MER

5. 9. Platelet inhibition and secondary prevention in cardiac surgery patients

   Författare :Erik Björklund; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; coronary artery bypass grafting; secondary prevention; bleeding complications; impedance aggregometry;

   Sammanfattning : ABSTRACT Background and objective Coronary artery bypass grafting (CABG) is the most common cardiac surgery procedure. Dual antiplatelet therapy (DAPT) reduces the risk for ischaemic events in patients with acute coronary syndrome (ACS) but increases the bleeding risk, both for spontaneous bleedings and procedure-related bleedings for the subset of ACS patients undergoing urgent CABG. LÄS MER

7. 10. Socioeconomic status and myocardial infarction : influence on secondary prevention and prognosis

   Författare :Joel Ohm; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : Background and Aims: In the wealth of research undertaken on myocardial infarctions (MIs), secondary prevention is less well studied. Incidence and death from MI have declined substantially in the past decades due to the identification of cardiovascular (CV) risk factors, methods to assess risk in the general population, development of efficient therapies that modify risk factor levels, and the introduction of revascularization therapies used in the acute phase of a MI. LÄS MER